Wockhardt Overview

  • Year Founded
  • 1967

Year Founded

  • Status
  • Public

  • Employees
  • 4,084

Employees

  • Stock Symbol
  • 532300

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $21.59
  • (As of Friday Closing)

Wockhardt General Information

Description

Wockhardt Ltd is a world-wide pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland and Dubai. The company's only reportable business segment is Pharmaceutical business. It has presence in India, USA, Europe, Rest of the world. The company generates majority of revenue from Europe.

Contact Information

Formerly Known As
Worli Chemical Works
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Wockhardt Towers
  • Bandra-Kurla Complex, Bandra (East)
  • Mumbai, 400051
  • India
+91 022
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
BOM
Corporate Office
  • Wockhardt Towers
  • Bandra-Kurla Complex, Bandra (East)
  • Mumbai, 400051
  • India
+91 022

Wockhardt Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wockhardt Stock Performance

As of 13-Nov-2026, Wockhardt’s stock price is $21.59. Its current market cap is $3.51B with 163M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$21.59 $21.95 $11.60 - $25.47 $3.51B 163M 78.2K $0.27

Wockhardt Financials Summary

As of 30-Sep-2026, Wockhardt has a trailing 12-month revenue of $405M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 3,781,339 2,206,782 2,979,960 1,369,597
Revenue 404,556 375,380 344,737 336,893
EBITDA 96,097 75,370 52,391 10,630
Net Income 44,220 24,105 (5,558) (55,927)
Total Assets 926,797 913,064 951,025 917,218
Total Debt 233,001 236,665 236,266 282,516
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Wockhardt Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Wockhardt‘s full profile, request access.

Request a free trial

Wockhardt Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Wockhardt Ltd is a world-wide pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and m
Pharmaceuticals
Mumbai, India
4,084 As of 2026

Bangalore, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Wockhardt Competitors (61)

One of Wockhardt’s 61 competitors is Strides Pharma Science, a Formerly VC-backed company based in Bangalore, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Strides Pharma Science Formerly VC-backed Bangalore, India
Evonile Pharma Private Equity-Backed Mumbai, India
Aurobindo Pharma Corporation Hyderabad, India
GSK Corporation London, United Kingdom
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
You’re viewing 5 of 61 competitors. Get the full list »

Wockhardt Patents

Wockhardt Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026146530-A1 Atorvastatin oral suspension with improved stability and a method for the production thereof Pending 30-Dec-2024
WO-2026133354-A1 A stable oral pharmaceutical composition of ferrous fumarate Pending 19-Dec-2024
WO-2026013693-A1 A stable prolonged release tablets of sodium valproate and valproic acid Pending 08-Jul-2024
AU-2025246337-A1 A stable oral liquid pharmaceutical formulation of clonidine Pending 29-Mar-2024
WO-2025203052-A1 A stable oral liquid pharmaceutical formulation of clonidine Pending 29-Mar-2024 A61K9/0095
To view Wockhardt’s complete patent history, request access »

Wockhardt Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Wockhardt Acquisitions (5)

Wockhardt’s most recent deal was a Merger/Acquisition with Laboratoires Negma for . The deal was made on 10-Nov-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Laboratoires Negma 10-Nov-2007 Merger/Acquisition Pharmaceuticals
Morton Grove Pharmaceuticals 23-Oct-2007 Merger/Acquisition Drug Delivery
Pinewood Healthcare 03-Oct-2006 Merger/Acquisition Pharmaceuticals
Esparma 06-May-2004 Merger/Acquisition Pharmaceuticals
CP Pharmaceuticals 15-Jul-2003 Merger/Acquisition Pharmaceuticals
To view Wockhardt’s complete acquisitions history, request access »

Wockhardt ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.52 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Wockhardt’s complete esg history, request access »

Wockhardt Exits (2)

Wockhardt’s most recent exit was on 23-Oct-2007 from Morton Grove Pharmaceuticals. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Morton Grove Pharmaceuticals 23-Oct-2007 Completed
Esparma 06-May-2004 Merger/Acquisition Completed
To view Wockhardt’s complete exits history, request access »

Wockhardt Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Pinewood Healthcare Clonmel, Ireland 1976

Wockhardt FAQs

  • When was Wockhardt founded?

    Wockhardt was founded in 1967.

  • Where is Wockhardt headquartered?

    Wockhardt is headquartered in Mumbai, India.

  • What is the size of Wockhardt?

    Wockhardt has 4,084 total employees.

  • What industry is Wockhardt in?

    Wockhardt’s primary industry is Pharmaceuticals.

  • Is Wockhardt a private or public company?

    Wockhardt is a Public company.

  • What is Wockhardt’s stock symbol?

    The ticker symbol for Wockhardt is 532300.

  • What is the current stock price of Wockhardt?

    As of 13-Nov-2026 the stock price of Wockhardt is $21.59.

  • What is the current market cap of Wockhardt?

    The current market capitalization of Wockhardt is $3.51B.

  • What is Wockhardt’s current revenue?

    The trailing twelve month revenue for Wockhardt is $405M.

  • Who are Wockhardt’s competitors?

    Strides Pharma Science, Evonile Pharma, Aurobindo Pharma, GSK, and Teva Pharmaceutical Industries are some of the 61 competitors of Wockhardt.

  • What is Wockhardt’s annual earnings per share (EPS)?

    Wockhardt’s EPS for 12 months was $0.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process